310 related articles for article (PubMed ID: 30009937)
1. Persistence of newer anti-obesity medications in a real-world setting.
Ganguly R; Tian Y; Kong SX; Hersloev M; Hobbs T; Smolarz BG; Ramasamy A; Haase CL; Weng W
Diabetes Res Clin Pract; 2018 Sep; 143():348-356. PubMed ID: 30009937
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the Efficacy of Anti-Obesity Medications in Real-World Practice.
Song JE; Ko HJ; Kim AS
Drug Des Devel Ther; 2024; 18():845-858. PubMed ID: 38524878
[TBL] [Abstract][Full Text] [Related]
3. THE BENEFIT OF SHORT-TERM WEIGHT LOSS WITH ANTI-OBESITY MEDICATIONS IN REAL-WORLD CLINICAL PRACTICE.
Shibuya K; Ali KF; Ji X; Milinoivh A; Bauman J; Kattan MW; Pantalone KM; Burguera B
Endocr Pract; 2019 Oct; 25(10):1022-1028. PubMed ID: 31241358
[No Abstract] [Full Text] [Related]
4. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S
JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618
[TBL] [Abstract][Full Text] [Related]
5. Utilization of Anti-obesity Medications After Bariatric Surgery: Analysis of a Large National Database.
Firkins SA; Chittajallu V; Flora B; Yoo H; Simons-Linares R
Obes Surg; 2024 May; 34(5):1415-1424. PubMed ID: 38512645
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Tak YJ; Lee SY
Curr Obes Rep; 2021 Mar; 10(1):14-30. PubMed ID: 33410104
[TBL] [Abstract][Full Text] [Related]
7. Overview of new antiobesity drugs.
Hainer V
Expert Opin Pharmacother; 2014 Oct; 15(14):1975-8. PubMed ID: 25100293
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience.
Calderon G; Gonzalez-Izundegui D; Shan KL; Garcia-Valencia OA; Cifuentes L; Campos A; Collazo-Clavell ML; Shah M; Hurley DL; Abu Lebdeh HS; Sharma M; Schmitz K; Clark MM; Grothe K; Mundi MS; Camilleri M; Abu Dayyeh BK; Hurtado Andrade MD; Mokadem MA; Acosta A
Int J Obes (Lond); 2022 Mar; 46(3):555-563. PubMed ID: 34811486
[TBL] [Abstract][Full Text] [Related]
9. Current and emerging pharmacotherapies for obesity in Australia.
Hocking S; Dear A; Cowley MA
Obes Res Clin Pract; 2017; 11(5):501-521. PubMed ID: 28818558
[TBL] [Abstract][Full Text] [Related]
10. Gender-related issues in the pharmacology of new anti-obesity drugs.
Cataldi M; Muscogiuri G; Savastano S; Barrea L; Guida B; Taglialatela M; Colao A
Obes Rev; 2019 Mar; 20(3):375-384. PubMed ID: 30589980
[TBL] [Abstract][Full Text] [Related]
11. Real-world primary nonadherence to antiobesity medications.
Kan H; Bae JP; Dunn JP; Buysman EK; Gronroos NN; Swindle JP; Bengtson LGS; Ahmad N
J Manag Care Spec Pharm; 2023 Oct; 29(10):1099-1108. PubMed ID: 37594848
[No Abstract] [Full Text] [Related]
12. A Comparison of New Pharmacological Agents for the Treatment of Obesity.
Nuffer W; Trujillo JM; Megyeri J
Ann Pharmacother; 2016 May; 50(5):376-88. PubMed ID: 26887340
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and persistence of anti-obesity medications (liraglutide 3 mg, lorcaserin, and orlistat) in a real-world primary care setting.
Leventhal-Perek S; Shani M; Schonmann Y
Fam Pract; 2023 Dec; 40(5-6):629-637. PubMed ID: 36477550
[TBL] [Abstract][Full Text] [Related]
14. Obesity Pharmacotherapy.
Saunders KH; Umashanker D; Igel LI; Kumar RB; Aronne LJ
Med Clin North Am; 2018 Jan; 102(1):135-148. PubMed ID: 29156182
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of new-generation anti-obesity medications: a narrative review.
Patel DK; Stanford FC
Postgrad Med; 2018 Mar; 130(2):173-182. PubMed ID: 29388462
[TBL] [Abstract][Full Text] [Related]
16. Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management.
Fujioka K; Braverman-Panza J
J Fam Pract; 2016 Jul; 65(7 Suppl):S16-23. PubMed ID: 27565106
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes associated with anti-obesity medications in real-world practice: A systematic literature review.
Ahmad NN; Robinson S; Kennedy-Martin T; Poon JL; Kan H
Obes Rev; 2021 Nov; 22(11):e13326. PubMed ID: 34423889
[TBL] [Abstract][Full Text] [Related]
18. Pharmacotherapy of obesity: Available medications and drugs under investigation.
Pilitsi E; Farr OM; Polyzos SA; Perakakis N; Nolen-Doerr E; Papathanasiou AE; Mantzoros CS
Metabolism; 2019 Mar; 92():170-192. PubMed ID: 30391259
[TBL] [Abstract][Full Text] [Related]
19. Obesity: The New Global Epidemic Pharmacological Treatment, Opportunities and Limits for Personalized Therapy.
Milano W; De Biasio V; Di Munzio W; Foggia G; Capasso A
Endocr Metab Immune Disord Drug Targets; 2020; 20(8):1232-1243. PubMed ID: 32410565
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the Risk Evaluation and Mitigation Strategy (REMS) for Phentermine-Topiramate to Prevent Exposure During Pregnancy.
Sarayani A; Donahoo WT; Hampp C; Brown JD; Winterstein AG
Ann Intern Med; 2023 Apr; 176(4):443-454. PubMed ID: 36940443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
